Treatment approaches to maximizing therapeutic response in migraine

Neurology

Volumn 61, Issue 8 SUPPL., 2003, Pages

  Brandes, Jan Lewis ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALMOTRIPTAN; ANTICONVULSIVE AGENT; IBUPROFEN; NAPROXEN; PARACETAMOL; RIZATRIPTAN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; ZOLMITRIPTAN;

AEROSOL; CHRONIC DISEASE; CLINICAL TRIAL; COMORBIDITY; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DRUG EFFECT; DRUG FORMULATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HORMONE ACTION; HUMAN; LOW DRUG DOSE; MIGRAINE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TABLET;

EID: 0344874585     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.61.8_suppl_4.s21     Document Type: Review

References (29)

1. Welch KM. Contemporary concepts of migraine pathogenesis. Neurology 2003;61(suppl 4):S2-S8.
2. Waeber C, Moskowitz M. Therapeutic implications of the central and peripheral neurologic mechanisms involved in migraine. Neurology 2003;61(suppl 4):S9-S20.
3. Lipton RB, Scher AI, Kolodner K, Liberman J, Steiner TJ, Stewart WF. Migraine in the United States: epidemiology and patterns of health care use. Neurology 2002;58:885-894.
4. Lipton RB, Stewart WF, Simon D. Medical consultation for migraine: results from the American Migraine Study. Headache 1998;38:87-96.
5. MacGregor EA, Brandes J, Eikermann A. Migraine prevalence and treatment patterns: the global Migraine and Zolmitriptan Evaluation (MAZE) survey. Headache 2003;43:19-26.
6. Drummond PD, Lance JW. Neurovascular disturbances in headache patients. Clin Exp Neurol 1984;20:93-96.
7. Stewart WF, Lipton RB, Whyte J, et al. An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology 1999;53:988-994.
8. Pryse-Phillips W. Evaluating migraine disability: the headache impact test instrument in context. Can J Neurol Sci 2002;29(suppl 2):S11-15.
9. Martin BC, Pathak DS, Sharfman MI, et al. Validity and reliability of the migraine-specific quality of life questionnaire (MSQ Version 2.1). Headache 2000;40:204-215.
10. Lipton RB, Stewart WF, Stone AM, Lainez MJ, Sawyer JP, for The Disability in Strategies of Care Study Group. Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: a randomized trial. JAMA 2000;284:2599-2605.
11. The International 311C90 Long-term Study Group. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine: an international study. Headache 1998;38:173-183.
12. Rapoport AM, Ramadan NM, Adelman JU, et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine: a multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group. Neurology 1997;49:1210-1218.
13. Syrett N, Abu-Shakra S, Yates R. Zolmitriptan nasal spray: Advances in migraine treatment. Neurology 2003;61(suppl 4):S27-S30.
14. Cady RK, Lipton RB, Hall C, Stewart WF, O'Quinn S, Gutterman D. Treatment of mild headache in disabled migraine sufferers: results of the Spectrum Study. Headache 2000;40:792-797.
15. Hu XH, Raskin NH, Cowan R, Markson LE, Berger ML, and the United States Migraine Study Protocol (USMAP) Group. Treatment of migraine with rizatriptan: when to take the medication. Headache 2002;42:16-20.
16. Pascual J, Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache 2002;42:28-31.
17. Klapper JA, Rosjo O, Charlesworth B, Jergensen AP, Soisson T. Treatment of mild migraine with oral zolmitriptan 2.5 mg provides high pain-free response rates in patients with significant migraine-related disability. Neurology 2002;58:A416. Abstract.
18. Klapper JA, Charlesworth B, Rosjo O, Jergensen AP, Soisson T. Treatment of mild migraine with oral zolmitriptan 2.5 mg prevents progression to more severe migraine and reduces the impact on normal activities in patients with significant migraine-related disability. Neurology 2002;58:A291. Abstract.
19. Burstein R, Yamamura H, Malick A, Strassman AM. Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neurophysiol 1998;79:964-982.
20. Yamamura H, Malick A, Chamberlin NL, Burstein R. Cardiovascular and neuronal responses to head stimulation reflect central sensitization and cutaneous allodynia in a rat model of migraine. J Neurophysiol 1999;81:479-493.
21. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol 2000;47:614-624.
22. Burstein R. Triptan therapy can abort migraine attacks if given before the establishment or in the absence of cutaneous allodynia and central sensitization: clinical and preclinical evidence. Headache 2002;42:390-391. Abstract.
23. Lipton RB, Hamelsky SW, Kolander KB, Steiner TJ, Stewart WF. Migraine, quality of life, and depression: a population-based case-control study. Neurology 2000;12:629-635.
24. Stewart WF, Linet MS, Celentano DD. Migraine headaches and panic attacks. Psychosoc Med 1989;51:559-569.
25. Swartz KL, Pratt LA, Armenian HK, Lee LC, Eaton WW. Mental disorders and the incidence of migraine headaches in a community sample: results from the Baltimore Epidemiologic Catchment area follow-up study. Arch Gen Psychiatry 2000;57:945-950.
26. Van Manen JG, Bindels PJ, Ijzermans CJ, van der Zee JS, Bottema BJ, Schade E. Prevalence of comorbidity in patients with a chronic airway obstruction and controls over the age of 40. J Clin Epidemiol 2001;54:287-293.
27. Brandes JL, Roberson SC. Impact of co-morbid depression on migraine disability in clinical practice: preliminary observations. Headache 2002;420. Abstract.
28. Lipton RB, Stewart WF. Migraine in the United States: a review of epidemiology and health care use. Neurology 1993;43(suppl 3):S6-10.
29. Loder E, Biondi D. Disease modification in migraine: a concept that has come of age? Headache 2003;43:135-143.